Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Accumulated Expenses (2016 - 2025)

IGC Pharma has reported Accumulated Expenses over the past 12 years, most recently at $886000.0 for Q3 2025.

  • Quarterly Accumulated Expenses fell 56.44% to $886000.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $886000.0 through Sep 2025, down 56.44% year-over-year, with the annual reading at $1.4 million for FY2025, 12.32% down from the prior year.
  • Accumulated Expenses was $886000.0 for Q3 2025 at IGC Pharma, up from $792000.0 in the prior quarter.
  • Over five years, Accumulated Expenses peaked at $2.0 million in Q3 2024 and troughed at $619000.0 in Q1 2023.
  • The 3-year median for Accumulated Expenses is $1.3 million (2023), against an average of $1.3 million.
  • Year-over-year, Accumulated Expenses skyrocketed 153.15% in 2024 and then crashed 56.44% in 2025.
  • A 3-year view of Accumulated Expenses shows it stood at $1.3 million in 2023, then soared by 41.46% to $1.8 million in 2024, then crashed by 51.37% to $886000.0 in 2025.
  • Per Business Quant, the three most recent readings for IGC's Accumulated Expenses are $886000.0 (Q3 2025), $792000.0 (Q2 2025), and $1.4 million (Q1 2025).